The Filing Desk

GeoVax Labs vs Lipocine

GeoVax Labs GOVX · Lipocine LPCN · Pharmaceuticals

GeoVax Labs reported revenue of $2 million in fiscal 2025, 1.2 times Lipocine's $2 million in fiscal 2025. GeoVax Labs' revenue fell 37.1% in its latest year, and Lipocine's fell 82.3%. GeoVax Labs had an operating margin of -869.3%, against -524.7% at Lipocine.

Side by side

GeoVax LabsLipocine
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$2M
Revenue growth−37.1%−82.3%
Revenue growth a year, last 5 years6.8%—
Gross margin——
Operating margin−869.3%−524.7%
Net margin−862.3%−487.1%
Free cash flow−$22M—
Free cash flow margin−863.8%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count361.9%5.3%
Last close$1.91$1.50
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
GeoVax LabsLipocine
Operating margin
Percent of revenue
GeoVax LabsLipocine
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
GeoVax LabsLipocine

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the GeoVax Labs and Lipocine pages.